Daxxify Injection, Powder, Lyophilized, For Solution
Product Images NDC 72960-112

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Daxxify (NDC 72960-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Revance Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Daxxify 01)

Figure 1 (Daxxify 01)
An anatomical diagram showing the frontal view of a human face focusing on the eyebrow region. It highlights specific injection points located along and above the eyebrows with measurements indicating 1 cm spacing for reference. The diagram likely illustrates recommended injection sites for botulinum toxin around the glabellar area between and above the eyebrows.*
FDA Label Image

Figure 2 (Study GL-1)

Figure 2 (Study GL-1)
A line graph titled Study GL-1 showing the percentage of subjects over study weeks for DAXXIFY and placebo groups. The graph includes lines for investigator and subject ratings of none or mild severity and treatment success, with percentages starting near zero, peaking early for DAXXIFY, and tapering off over 36 weeks.*
FDA Label Image

Figure 2 (Study GL-2)

Figure 2 (Study GL-2)
A line graph from Study GL-2 showing the percentage of subjects over 36 study weeks. The graph compares DAXXIFY with placebo using three different lines: 'None or mild - Investigator' (dashed), 'None or mild - Subject' (dash-dotted), and 'Treatment Success' (solid). The DAXXIFY lines show a sharp rise above placebo early in the study, followed by a gradual decline over time.*
FDA Label Image

Principal Display Panel (1.2 mL Vial Carton)

Principal Display Panel (1.2 mL Vial Carton)
Packaging label for DAXXIFY 100 units/vial injection, a lyophilized powder for intramuscular solution by Revance Therapeutics, Inc. The label includes dosage strength, single-dose vial indication, storage instructions, a barcode, and regulatory warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.